janux therapeutics is an innovative biopharmaceutical company developing next-generation therapeutics based on its proprietary tumor activated t cell engager (tractr) platform technology to better treat patients suffering from cancer. janux’s initial focus is on developing a novel class of t cell engagers (tces), and its lead product candidates are designed to target clinically validated drug targets. while tce therapeutics have displayed potent anti-tumor activity in hematological cancers, developing tces to treat solid tumors have faced challenges due to the limitations of prior tce technologies, namely (i) overactivation of the immune system leading to cytokine release syndrome, (ii) on-target, healthy tissue toxicities, and (iii) poor pharmacokinetics leading to short half-life. janux is using its tractr platform technology to engineer product candidates designed to overcome these limitations. janux is developing a broad pipeline with lead programs targeting prostate-specific membr
Company profile
Ticker
JANX
Exchange
Website
CEO
David Alan Campbell
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
SEC CIK
Corporate docs
IRS number
822289112
JANX stock data
Latest filings (excl ownership)
S-8
Registration of securities for employees
8 Mar 24
10-K
2023 FY
Annual report
8 Mar 24
8-K
Janux Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Business Highlights
8 Mar 24
424B5
Prospectus supplement for primary offering
29 Feb 24
8-K
Janux Therapeutics Announces Proposed Public Offering of Common Stock
29 Feb 24
FWP
Free writing prospectus
28 Feb 24
8-K
Other Events
28 Feb 24
424B5
Prospectus supplement for primary offering
27 Feb 24
8-K
Other Events
27 Feb 24
8-K
83% (5/6) of subjects achieved PSA50 declines with first step dose ≥ 0.2mg
26 Feb 24
Latest ownership filings
SC 13D/A
RA CAPITAL MANAGEMENT, L.P.
6 Mar 24
4
Rajeev M. Shah
6 Mar 24
SC 13D/A
Avalon Ventures XI, L.P.
4 Mar 24
4
Change in insider ownership
4 Mar 24
4
Sheila Gujrathi
4 Mar 24
4
VICKIE L CAPPS
4 Mar 24
SC 13G/A
EcoR1 Capital, LLC
14 Feb 24
SC 13G/A
CITADEL ADVISORS LLC
14 Feb 24
SC 13G/A
BIOTECHNOLOGY VALUE FUND L P
14 Feb 24
SC 13G/A
Campbell David Alan
9 Feb 24
Financial summary
Quarter (USD) | Sep 23 | Jun 23 | Mar 23 | Dec 22 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 22 | Dec 21 | |
---|---|---|---|
Revenue | |||
Cost of revenue | |||
Operating income | |||
Operating margin | |||
Net income | |||
Net profit margin | |||
Cash on hand | |||
Change in cash | |||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 17.97 mm | 17.97 mm | 17.97 mm | 17.97 mm | 17.97 mm | 17.97 mm |
Cash burn (monthly) | 5.52 mm | 3.97 mm | 5.27 mm | 6.26 mm | 3.90 mm | 4.38 mm |
Cash used (since last report) | 37.78 mm | 27.16 mm | 36.09 mm | 42.86 mm | 26.73 mm | 30.01 mm |
Cash remaining | -19.81 mm | -9.19 mm | -18.13 mm | -24.89 mm | -8.76 mm | -12.04 mm |
Runway (months of cash) | -3.6 | -2.3 | -3.4 | -4.0 | -2.2 | -2.7 |
Institutional ownership, Q3 2023
91.8% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 60 |
Opened positions | 9 |
Closed positions | 7 |
Increased positions | 23 |
Reduced positions | 16 |
13F shares | Current |
---|---|
Total value | 353.44 bn |
Total shares | 47.45 mm |
Total puts | 400.00 |
Total calls | 2.40 k |
Total put/call ratio | 0.2 |
Largest owners | Shares | Value |
---|---|---|
Ra Capital Management | 9.17 mm | $92.39 bn |
FMR | 6.35 mm | $64.02 bn |
BVF | 4.58 mm | $46.16 bn |
Avalon Ventures XI | 4.48 mm | $83.23 mm |
Biotechnology Value Fund L P | 4.11 mm | $49.28 mm |
Bregua | 3.75 mm | $69.66 mm |
Citadel Advisors | 3.43 mm | $34.59 bn |
Orbimed Advisors | 3.32 mm | $33.44 bn |
JHG Janus Henderson | 2.07 mm | $20.82 bn |
BLK Blackrock | 1.64 mm | $16.53 bn |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
29 Feb 24 | Capps Vickie L | Common Stock | Other | Acquire J | No | No | 0 | 1,493 | 0.00 | 65,543 |
29 Feb 24 | Gujrathi Sheila | Common Stock | Other | Acquire J | No | No | 0 | 2,986 | 0.00 | 108,028 |
29 Feb 24 | Avalon Ventures XI | Common Stock | Other | Dispose J | Yes | No | 0 | 1,700 | 0.00 | 0 |
29 Feb 24 | Avalon Ventures XI | Common Stock | Other | Acquire J | Yes | No | 0 | 1,700 | 0.00 | 1,700 |
29 Feb 24 | Avalon Ventures XI | Common Stock | Other | Dispose J | Yes | No | 0 | 84,985 | 0.00 | 764,869 |
29 Feb 24 | Avalon Ventures XI | Common Stock | Other | Dispose J | Yes | No | 0 | 31,456 | 0.00 | 0 |
29 Feb 24 | Avalon Ventures XI | Common Stock | Other | Acquire J | Yes | No | 0 | 31,456 | 0.00 | 31,456 |
29 Feb 24 | Avalon Ventures XI | Common Stock | Other | Dispose J | Yes | No | 0 | 447,949 | 0.00 | 4,031,543 |
29 Feb 24 | Avalon Ventures XI | Common Stock | Other | Dispose J | Yes | No | 0 | 11,388 | 0.00 | 0 |
29 Feb 24 | Avalon Ventures XI | Common Stock | Other | Acquire J | Yes | No | 0 | 11,388 | 0.00 | 11,388 |
News
A Glimpse Into The Expert Outlook On Janux Therapeutics Through 6 Analysts
16 Apr 24
JonesTrading Initiates Coverage On Janux Therapeutics with Buy Rating, Announces Price Target of $70
16 Apr 24
Why Fastenal Shares Are Trading Lower By Around 7%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
11 Apr 24
Why Is Cancer-Focused Janux Therapeutics Stock Trading Higher On Thursday?
11 Apr 24
Enliven Therapeutics, Alpine Immune Sciences, Janux Therapeutics And Other Big Stocks Moving Higher On Thursday
11 Apr 24
Press releases
Janux Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Business Highlights
8 Mar 24
Janux Therapeutics Announces Pricing of $296.5 Million Underwritten Public Offering of Common Stock and Pre-Funded Warrants
29 Feb 24
Janux Therapeutics Announces Proposed Public Offering of Common Stock
27 Feb 24
Thinking about buying stock in BigBear.ai, Janux Therapeutics, Surf Air Mobility, Bank of Nova Scotia, or Bellerophon Therapeutics?
27 Feb 24